Immunoclassification of Psoriasis: a Strategy for Precision Medicine

NCT05503875 · tracked via the Priya Life Science China tracker

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine

Phase

Not applicable

Started

2023-01-01

Last updated

2024-01-12

Condition(s) studied

ImmunoclassificationPsoriasis

Investigational drug(s) / intervention(s)

adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate

adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate: Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.

Study summary

Through the combination of clinical manifestations and omics, the investigators aim to explore the skin cell atlas in different stages of psoriasis lesions, establish a clinical classification standard for psoriasis, and guide the precise treatment of psoriasis.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Accepted

Inclusion Criteria: 1.18 to 75 years of age 2.Moderate to severe chronic psoriasis, BSA≥3% 3.Duration of psoriasis≥6 months 4.Patients must be candidate for systemic therapy 5.Informed consent must be obtained 6.For female, ß-hCG test is negative and contraception is accepted Exclusion Criteria: 1. Having severe infections, including hepatitis, HIV and tuberculosis 2. Having significant allergies to biological agents 3. Having a history of malignancy 4. Refusal of contraception 5. Having serious or unstable/uncontrolled illnesses

Primary outcome measure(s)

Differences in the number of immune cells (dendritic cells, macrophages) in the lesional skin, non-lesional skin of psoriasis patients and healthy skin. — 16 months
The intensity of specific cell subsets will be assessed by flow cytometry in psoriasis patients and healthy controls.
Molecular analysis of psoriasis lesional skin by single-cell RNA sequencing. — 16 months
To analyze the intensity of cytokines or chemokines, such as IL-17, IL-23, TNF in the dermis and epidermis of psoriasis patients

Trial sites (1)

Facility	City	Region	Status
2nd Affiliated Hospital, School of Medicine, Zhejiang University	Hangzhou	Zhejiang	Recruiting

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury Recruiting

Epidural Electrical Stimulation in Spinal Cord Injury Recruiting

Research on the Protective Effects of Phycocyanin Against Liver Fibrosis and Cirrhosis Recruiting

A Functional Near- Infrared Spectroscopy Study on the Brain Activation Characteristics of Stroke Patients During Mirror Movement Recruiting

Clinical Study of Acupoint Application on Relieving qi Deficiency and Constipation in Patients Undergoing Chemotherapy Recruiting

Other trials for the same condition

A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis Recruiting

A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis Recruiting

Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis Starting soon

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118 Recruiting

Machine Learning-Based Prediction of Insulin Resistance in Psoriasis Patients Emphasizing Interpretability Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05503875 on ClinicalTrials.gov ↗ ← All trials in China